HAYA Therapeutics’ Post

🎧 Did you catch this episode of Molecule to Market: From banking to biotech In this episode, Raman Sehgal is joined by Audrey Greenberg, Co-founder of the Center for Breakthrough Medicines - now part of SK pharmteco Together, they discuss: 👉 How a career in real estate financial services led her to the world of CGT 👉 The story of the creation of the Center for Breakthrough Medicines to its eventual sale and 'fit' with SK Pharmteco 👉Why Philadelphia's "Cellicon Valley" is becoming one of the hottest life science clusters in the US Listen below, you don't want to miss it! #PharmaPodcast #CDMO #Podcast

In the latest episode of Healio’s Oncology Overdrive podcast, our Co-founder and Chief Scientific Officer, Brian Fiske, Ph.D., joined Shikha Jain, MD, FACP to discuss entrepreneurship in #biotech, #ADC developments and more. Tune in to learn how his career through biotech has helped shape his current role at Mythic as we strive to develop better ADCs for patients everywhere.    Listen here: https://bit.ly/4eqUvEs    Healio | HemOnc Today  

🚀 15-Minute Weekly Roundup: Insights for the Business Week Ended March 8, 2024 🔍 Another fantastic episode by Ian Haydock! Let’s dive into the key highlights: - Bayer AG: No Split (for Now) Despite speculation, Bayer AG has decided to remain intact. The company won’t split at this time. - Pfizer Inc.'s Next-Gen ADC Pipeline Pfizer is making strides in the field of antibody-drug conjugates (ADCs). Exciting developments lie ahead! - Oncology Dominates Investment Investors continue to pour resources into oncology research and development. A trend that shows no signs of slowing down. - Goodbye NASH, Hello MASH The focus is shifting from Non-Alcoholic Steatohepatitis (NASH) to Metabolic Associated Steatohepatitis (MASH). Keep an eye on this transition. - Bristol Myers Squibb CEO’s Views on India Insights from the top! The CEO of Bristol Myers Squibb shares perspectives on the Indian market.

M&A the comeback kid but there are more. Check out our latest podcast on hot trends, topics of #China #biotech #dealmaking #mergersandacquisitions

How are companies like Vera Therapeutics, Inc. advancing autoimmune disease treatments? What does the current landscape of the biotech industry look like? Vera Therapeutics CEO and Founder Marshall Fordyce, M.D. joined host Rahul Chaturvedi on the Biotech2050 podcast to answer these questions. Dr. Fordyce also shares his entrepreneurial journey and delves into Vera Therapeutics' strategic pivot to focus on IG nephropathy and Vera’s development of atacicept, a promising B-cell modulator. Tune in: https://lnkd.in/eqHFpe4B #Biotech #AutoimmuneDisease

Delighted to unveil the newest #Biotech 2050 episode with Marshall Fordyce, M.D. Fordyce, the innovative Founder & CEO of Vera Therapeutics, Inc.! 🎙️ In this episode, Host Rahul Chaturvedi joins Marshall as they delve into his transformative journey from physician to biotech entrepreneur, offering invaluable perspectives on the biotech industry. Discover how Vera Therapeutics pivoted to focus on IG nephropathy and their groundbreaking work with atacicept, a promising B-cell modulator. Key highlights include: 🔹 The importance of scientific rigor and adaptability 🔹 Navigating the biotech landscape 🔹 Future outlook on autoimmune disease treatments Whether you're an aspiring entrepreneur or a seasoned professional, Marshall's insights on maintaining a lean operating model and driving innovation are a must-listen. 🎧 Tune in now and get inspired by the future of autoimmune disease treatments: https://lnkd.in/eaq7isNN #Biotech #Autoimmune #Innovation #Healthcare #BiotechBreakthroughs #Podcast #MedicalResearch #ClinicalTrials #DrugDevelopment #HealthcareInnovation #Entrepreneurship

Check out the new episode of Biotech2050, hosted by Clora CEO, Rahul Chaturvedi, where he welcomes back former guest Marshall Fordyce, M.D., the Founder & CEO of Vera Therapeutics, Inc., after two years. In this episode, Marshall delves into Vera Therapeutics' strategic pivot from an initial gene editing platform to autoimmune and rare kidney diseases, specifically the story of atacicept as a dual BAFF/APRIL B cell modulator for IgA Nephropathy (IgAN), a B cell-mediated kidney disease that often progresses to kidney failure. Leveraging a value-creating lens, Marshall provides key insights into the importance of scientific rigor in biotech, adapting to the evolving biotech landscape, and maintaining a lean and effective operating model. Don't miss out on this must-listen episode! Tune in using the link below. #Clora #podcast #biotech #entrepreneur #leadership #autoimmunedisease #drugdevelopment #IgAN #kidneydisease

A new episode of Antibody News podcast has just been published! Now available for FREE on all major podcast platforms! #podcast #businessintelligence #antibodytherapeutics #mabs #antibodynews

In the second episode of #AtTheCrossing, host Abe Sutton and guest Theo Merkel discuss how Medicare Part B sets prices for new drugs and a proposal Theo authored to use market forces to negotiate rates. #AtTheCrossing is a Rubicon Founders podcast detailing how healthcare really works and exploring solutions to today’s toughest problems. This series brings you commentary and perspective from thought-leaders and entrepreneurs who know what it takes to transform healthcare. https://lnkd.in/efFjW5-e

In an episode of The BioHub Podcast, Lisata President and CEO, David J. Mazzo, Ph.D., speaks with Max Brennan, MSc. The two discuss the progress of Lisata, as well as how the pharmaceutical and biotech landscapes have evolved. Dr. Mazzo speaks on his 40 years of experience in the pharmaceutical field and the development of certepetide, Lisata’s novel product candidate. Watch the full episode: https://lnkd.in/etBPgtu4 #LisataTherapeutics #Oncology